Xencor
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Xencor sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
Xencor: 27 sponsored US clinical trials, 3 recruiting.
Xencor sponsors 27 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 16 completed. 0 of these trials are in Phase 3-4 (later-stage) and 27 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Endometrial Cancer, with 2 trials.
Top-decile sponsor footprint
Xencor ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
27 total, page 1 of 1
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
NCT06619990
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
NCT07593092
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
NCT06173505
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05996445
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT05585034
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
NCT06005792
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
NCT05328102
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT05005728
Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer
NCT04590781
Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers
NCT04857866
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
NCT03849469
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT03752398
Study Evaluating AMG 424 in Subjects With Multiple Myeloma
NCT03445663
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03517488
A Study of XmAb®18087 in Subjects With NET and GIST
NCT03411915
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
NCT02924402
Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195
NCT02881853
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
NCT02730312
XmAb5871 Bioavailability Study
NCT02867098
Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)
NCT02725476
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
NCT02148744
Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia
NCT01161511
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
NCT00606645
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 5 |
What is open in the Xencor pipeline
3 recruiting of 27 indexed (11% open); 16 completed (59%).
Phase mix: 0 late (III/IV) vs 27 early (I/II) (early-phase heavy).
Top condition: Endometrial Cancer (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Xencor: open-pipeline peers nationwide
Peers matched on 27 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Xencor sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 trials (± recruiting share)
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
Sponsors near 11% open enrollment (± trial volume)
- ADC Therapeutics S.A. · 11% recruiting · 18 trials
- Adrian Vella · 11% recruiting · 9 trials
- AIDS Malignancy Consortium · 11% recruiting · 45 trials
- Amylyx Pharmaceuticals · 11% recruiting · 9 trials
Related
What to do with this Xencor page
27 registered trials is a research-attention snapshot, not an endorsement of Xencor or any single study.
- 3 of Xencor's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Endometrial Cancer is the condition Xencor studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Endometrial Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Xencor pipeline card: 27 registered trials from official public datasets.Report a data error.